Abstract Number: 1841 • ACR Convergence 2022
To Combine or Not to Combine: Influence of Immunosuppressive Drug Combination in the Induction of Therapeutic Response in Non-infectious Uveitis
Background/Purpose: Non-infectious uveitides (NIUs) include a heterogeneous group of sight-threatening and incapacitating conditions. Their correct management sometimes requires the use of immunosuppressive drugs (ISDs), prescribed…Abstract Number: 2123 • ACR Convergence 2022
Hierarchical Ranking of Biologic Disease-Modifying Antirheumatic Drugs and Targeted Systemic Therapies for Psoriatic Arthritis: A Network Meta-analysis
Background/Purpose: There are an increasing number of biological and targeted DMARDs in PsA. However, challenges around treatment selection remain, given the few head-to-head studies directly…Abstract Number: 0067 • ACR Convergence 2022
Cost Per Responder in RA Patients Failing First Line Treatment
Background/Purpose: The Colombian healthcare system is under economic pressure like many other systems in the world. In that sense, treatment choice involves cost in addition…Abstract Number: 0289 • ACR Convergence 2022
Real-world Data of Tofacitinib versus Tumor Necrosis Factor Inhibitors in Taiwanese Patients with Rheumatoid Arthritis from a Drug-based Registry
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA and was approved under Taiwan's National Health Insurance (NHI) reimbursement system in…Abstract Number: 0414 • ACR Convergence 2022
Efficacy and Safety of Upadacitinib in Patients with Ankylosing Spondylitis with Intolerance to And/or Lack of Efficacy of Prior Biologic Therapy: A Subgroup Analysis
Background/Purpose: Upadacitinib (UPA), an oral Janus kinase inhibitor, has been evaluated in the treatment of AS both in patients (pts) naïve to biologic DMARDs (bDMARDs)1…Abstract Number: 0765 • ACR Convergence 2022
The Impact of Immunomodulating Treatment on the Immunogenicity of COVID-19 Vaccines in Patients with Immune-mediated Inflammatory Rheumatic Diseases Compared to Healthy Controls. a Swedish Nationwide Study (COVID19-REUMA)
Background/Purpose: The aim of the study was to elucidate antibody responses after vaccination with two doses of COVID-19 vaccines in patients with inflammatory rheumatic diseases…Abstract Number: 0919 • ACR Convergence 2022
Predictors of Methotrexate Monotherapy Response in Patients with Active Rheumatoid Arthritis: Results from a Multicentre, Randomized Controlled Trial
Background/Purpose: Methotrexate (MTX) is the gold standard, first-line therapy for rheumatoid arthritis (RA). However, not all patients respond to MTX, and the predictors of its…Abstract Number: 1125 • ACR Convergence 2022
Genomics of JAK-STAT Signaling in Venous Thromboembolism
Background/Purpose: Janus kinase inhibitors (JAKi) have been associated with an increased risk of venous thromboembolism (VTE). This concern limits the use of JAKi-based therapy. Hence,…Abstract Number: 1427 • ACR Convergence 2022
Impact of Upadacitinib versus Abatacept on Individual Disease Outcomes in Patients with Rheumatoid Arthritis and Inadequate Responses to Biologic DMARDs
Background/Purpose: The phase 3 SELECT-CHOICE trial of patients with rheumatoid arthritis (RA) and prior inadequate response to biologic DMARD(s) (bDMARD-IR) demonstrated superiority of the JAK…Abstract Number: 1843 • ACR Convergence 2022
Trends in the Cumulative Exposure to Corticosteroids in Polymyalgia Rheumatica (PMR) Patients: A Single Academic Center Experience
Background/Purpose: Polymyalgia rheumatica (PMR) treatment is predominantly based on long-term corticosteroids, which results in significant corticosteroid-related toxicities. Studies1,2 have shown patients with PMR are exposed…Abstract Number: 2126 • ACR Convergence 2022
Impact of Risankizumab on Enthesitis and Dactylitis: Integrated Analysis of the Phase 3, Randomized, Double-Blind KEEPsAKE 1 and 2 Trials
Background/Purpose: Psoriatic arthritis (PsA) is a progressive condition with chronic inflammation and joint destruction impacting quality of life.1 Dactylitis and enthesitis are clinically relevant domains…Abstract Number: 0073 • ACR Convergence 2022
Opioid and Pain Medication Prescribing by Rheumatologists for Medicare Part D Beneficiaries from 2013 to 2019
Background/Purpose: Prescription opioid medications are highly effective in managing acute pain, but their use for chronic pain remains controversial. The objective of this study is…Abstract Number: 0290 • ACR Convergence 2022
Evaluation of Treatment Discontinuation Due to Adverse Events, and the Effect of Cardiovascular Risk Factors or Type of JAK-inhibitors: An International Collaboration of Registries of Rheumatoid Arthritis Patients (the ‘JAK-pot‘ Study)
Background/Purpose: The "ORAL Surveillance" study1 suggests an increased risk of serious adverse events (AEs) with tofacitinib, a JAK-inhibitor (JAKi), compared to TNF-inhibitors (TNFi). Currently, there…Abstract Number: 0421 • ACR Convergence 2022
Efficacy and Safety of Tofacitinib in Patients with Ankylosing Spondylitis by Prior bDMARD Treatment: Analysis of a Phase 3 Trial
Background/Purpose: Prior exposure to biologic (b)DMARD therapy of patients (pts) with AS may influence treatment response.1-3 Tofacitinib is an oral JAK inhibitor for the treatment…Abstract Number: 0787 • ACR Convergence 2022
Relationship Between Humoral and Cellular Immune Responses in Persons with Rheumatoid Arthritis Following a Third Dose of COVID-19 Vaccine
Background/Purpose: DMARDs that treat RA may reduce immune responses to COVID-19 vaccination. We compared measures of humoral and cell-mediated immunity in RA patients before and…
- « Previous Page
- 1
- …
- 20
- 21
- 22
- 23
- 24
- …
- 40
- Next Page »